Torrent Pharmaceuticals Ltd.

NSE: TORNTPHARM | BSE: 500420 | ISIN: INE685A01028 | Industry: Pharmaceuticals
| Expensive Performer
3117.85 -47.30 (-1.49%)
NSE Jan 24, 2022 15:31 PM
Volume: 116.8K
 

3117.85
-1.49%

Highlights

  • Revenue at Rs. 2,137 crores up by 6%
  • Gross margins: 72.2%; EBITDA margins: 33.2%
  • EBITDA at Rs. 711 crores was up by 11%.
  • Profit before tax at Rs. 472 crores was up by 23%.
  • Net profit after tax at Rs. 316 crores was up 2%
     
  • India:
    • India revenues at Rs 1,087 crores grew by 13%
    • Underlying growth adjusted for dispatch related delays last year is at 16%
    • As per secondary market data (AIOCD), Torrent’s Q2 FY22 growth was 19% versus IPM growth of 15%
    • Torrent has outperformed the market in all its key therapies during the quarter.
    • MR productivity for the quarter was Rs 9.9 lakhs with MR strength of 3,600
    • For H1 FY22, revenues were Rs 2,180 crores, up by 15%.
  • United States:
    • US revenues at Rs 284 crores, were down by 13%.
    • Constant currency sales were $35 million.
    • Sales were lower due to price erosion in the base business and lack of new approvals pending re-inspection of facilities.
    • As on September 30, 2021, 53 ANDAs were pending approval with USFDA and 7 tentative approvals were received. 1 ANDA was approved during the quarter.
    • For H1 FY22, revenues were Rs 550 crores, down by 21% (Constant currency sales: $71 million).
  • Brazil:
    • Brazil revenues at Rs 156 crores, were up by 21%
    • Constant currency sales at R$ 109 million.
    • Brazil BGx market growth is at 10% during the quarter.
    • Growth was driven by momentum in the large brands combined with the strong launch of two new products.
    • For H1 FY22, revenues were Rs 309 crores, up by 15% (Constant currency sales: R$ 218 million, up by 16%).
  • Germany:
    • Germany revenues at Rs 251 crores were down by 4%
    • Constant currency sales were Euro 29 million.
    • Growth during the quarter was mainly impacted due to covid induced supply delays and inventory normalization led by customer consolidation at market place.
    • Secondary sales trend was in-line with market growth.
    • For H1 FY22, revenues were Rs 510 crores, up by 1% (Constant currency sales: Euro 58 million).

Result PDF

default
Torrent Pharmaceuticals Ltd. is trading above it's 200 day SMA of 2950.0
Recommended